Why Is Legend Biotech Stock Falling Thursday?

Legend Biotech (LEGN) stock fell 7.52% in premarket trading Thursday after the cell therapy company announced an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million. The decline comes despite the company's strong market position and analyst Buy rating with a $58.57 price target, though recent earnings showed a wider-than-expected loss and revenue slightly below consensus.

06/18/2026, 8:27 AM • Benzinga

Legend Biotech Corporation Announces Pricing of Public Offering

Legend Biotech Corporation announced the pricing of an underwritten public offering of 7.7 million American Depositary Shares at $29.35 per ADS, expected to raise approximately $226 million in gross proceeds. The offering is expected to close on June 23, 2026, with Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities serving as joint book-running managers.

06/17/2026, 9:21 PM • GlobeNewswire

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Legend Biotech announced positive Phase 1 clinical data for LB2501, an investigational in vivo CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. The therapy achieved 100% objective response rate and 83.3% complete response rate at the higher dose level following a single infusion without lymphodepletion, with a favorable safety profile showing no dose-limiting toxicities, serious adverse events, or ICANS.

06/14/2026, 3:15 AM • GlobeNewswire

Why Legend Biotech Stock Crushed the Market on Monday

Legend Biotech (LEGN) surged 18% on Monday following bullish analyst updates from H.C. Wainwright and RBC Capital. The rally was partly inspired by Eli Lilly's $7 billion acquisition of Kelonia Therapeutics, a CAR-T therapy developer similar to Legend. Analysts highlighted Legend's promising pipeline programs, including encouraging progress on its CD19/CD20 dual-targeted therapy.

04/20/2026, 6:16 PM • The Motley Fool

Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares

Suvretta Capital Management sold nearly 1.1 million shares of Arcutis Biotherapeutics (ARQT) during Q3, reducing its position by $35.78 million. Despite the sale, ARQT remains the fund's largest holding worth $197.51 million. The stock has doubled in value over the past year, significantly outperforming the S&P 500. The sale appears to be a risk management decision following the dramatic stock appreciation rather than a loss of conviction in the company's fundamentals.

12/23/2025, 12:18 PM • The Motley Fool

Earlier use of CARVYKTI®▼ (ciltacabtagene autoleucel) demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma

A study of CARVYKTI® demonstrated lasting treatment-free remissions in 80% of standard-risk multiple myeloma patients when used as early as second-line therapy, with improved immune fitness potentially correlating with longer progression-free survival.

12/06/2025, 9:30 AM • GlobeNewswire

Legend Biotech Awarded 2025 FIBA Foreign Investor of the Year by Flanders Investment & Trade

Legend Biotech was awarded Foreign Investor of the Year at the 2025 Flanders International Business Awards for its €165 million investment with Johnson & Johnson to expand cell therapy manufacturing in Ghent, Belgium, growing from 2 to over 1,000 employees.

11/27/2025, 9:00 AM • GlobeNewswire

Gene Therapies for Cancer Treatment Market Projects USD 238.77 Billion at 39.94% CAGR by 2034

The global gene therapies for cancer treatment market is expected to grow from $8.28 billion in 2024 to $238.77 billion by 2034, with a 39.94% CAGR. North America currently dominates the market, with CAR-T cell therapy leading market share and significant innovations driving growth.

11/17/2025, 10:00 AM • GlobeNewswire